President Trump's "One Big, Beautiful Bill" faces opposition from within his party as lawmakers debate work requirements for Medicaid and food stamps, tax cuts, and spending reductions.

But the FDA declared months ago that the shortages of semaglutide and tirzepatide injections had ended, effectively ending flexibilities for compounded products. The grace period for manufacturers to ...